口服补充剂不会影响胰岛素治疗2型糖尿病和血清含量低的人的胰岛素敏感性:一项随机对照试验
Linda C A Drenthen1, Jeroen H F de Baaij2, Laura Rodwell3
1Department of Internal Medicine, Radboudumc, Nijmegen, the Netherlands. linda.drenthen@radboudumc.nl.
Diabetologia
|November 3, 2023
概括
补充并没有改善2型糖尿病和低水平的个体的胰岛素敏感性,尽管血清的温和增加. 需要进一步的研究来探索的含量.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
背景情况:
- 低磁血症与胰岛素耐药性和2型糖尿病风险增加有关.
- 在低的2型糖尿病患者中,补充剂对胰岛素敏感性的疗效尚未得到充分证实.
研究的目的:
- 调查口服补充剂是否会提高胰岛素治疗2型糖尿病和低血清水平的个体的胰岛素敏感性.
主要方法:
- 一个随机,双盲,安慰剂控制,交叉研究.
- 14名接受胰岛素治疗的2型糖尿病和血清含量低的参与者接受了口服 (15 mmol/天) 或安慰剂6周.
- 胰岛素敏感性通过使用高胰岛素性-高血糖性 (M值) 进行评估.
主要成果:
- 与安慰剂相比,补充增加了血清水平和尿道分泌量.
- 在和安慰剂组之间没有观察到M值 (胰岛素敏感性) 的显著差异.
- 没有发现葡萄糖控制,胰岛素剂量,脂质概况或血压的改善,而的HDL胆固醇略有下降.
结论:
- 口服补充剂不会改善2型糖尿病和低水平的个体的胰岛素敏感性.
- 血清的适度增加并没有转化为增强的葡萄糖代谢或胰岛素敏感性.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Sulfonylureas
214
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
214
Insulin: Dosing Regimen and Adverse Effects
184
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
184
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
183
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
183
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K


